Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

Carboplatin 11pembrolizumab 10Gemcitabine 8Cisplatin 8Rituximab 7osimertinib 5durvalumab 5Specimen Handling 5Pemetrexed 5Nivolumab 5Dexamethasone 5belzutifan 4atezolizumab 4amivantamab 4Prednisone 4Paclitaxel 4Cyclophosphamide 4Bortezomib 4trastuzumab deruxtecan 3olaparib 3lazertinib 3entrectinib 3enfortumab vedotin 3daratumumab 3alectinib 3acalabrutinib 3X-Rays 3Vinorelbine 3Oxaliplatin 3Midazolam 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × daratumumab × 90 days × Clear all
NCT03652064 2026-06-02

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Janssen Research & Development, LLC

Phase 3 Completed
395 enrolled 11 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT05083169 2026-05-08

MajesTEC-3

Janssen Research & Development, LLC

Phase 3 Active not recruiting
587 enrolled 1 FDA
Plasma cell

Multiple Myeloma

NCT04246047 2026-04-23

DREAMM 7

GlaxoSmithKline

Phase 3 Active not recruiting
494 enrolled 10 charts 1 FDA
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡